APM
Aptorum Group Limited
NASDAQ · Healthcare · Biotechnology · GB
$8.26
−14.84%Year over year
Reported trailing growth
- Revenue
- -19.9%
- EBITDA
- +51.3%
- EBIT
- +71.7%
- EPS
- -44.2%
- Free cash flow
- +87.4%
- Operating cash flow
- +87.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +51.6%
- EBIT
- +52.1%
- Net income
- +68.1%
- EPS
- +75.6%
- Free cash flow
- -54.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026